In the pharmaceutical industry, “low-see HCPs,” and "no-see HCPs" represent a significant and growing challenge. These are healthcare providers who, for various reasons, opt not to meet with pharmaceutical sales representatives. This trend has a considerable impact on market access and how pharmaceutical companies approach marketing and sales strategies, particularly in the realm of pharma market access. In this blog, we will delve into the reasons behind the no-see phenomenon, its implications for pharma marketing and market access strategies, and potential approaches for addressing this challenge. The rise of no-see HCPs significantly influences the strategies for market access in pharma, prompting a reevaluation of traditional marketing and sales methodologies.
Here is everything you need to know about low and no-see HCPs: